The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
The synthesis of several hydrocarbon biradicals consisting of two tetraphenylcyclopentadienyl moieties with different bridge fragments is described. The ESR powder spectra show that there is an intramolecular coupling of two unpaired electron spins to a triplet spin state. The magnitude of the zero field splitting (zfs) is used to discriminate between different molecular conformations. More detailed
Dicyanoaromatic radical anions as mixed valence species
作者:Álvaro Moneo、M. Fernanda N. N. Carvalho、João P. Telo
DOI:10.1002/poc.2905
日期:2012.7
The reduction of nine symmetric dicyanoaromatic radicalanions by sodium amalgam in the presence of cryptand[2.2.2] was studied using cyclic voltammetry and using optical and electron paramagnetic resonance (EPR) spectroscopies in two aprotic solvents. All radicals are charge‐delocalized (Class III) mixedvalence species, as shown by the weak solvatochromism of their low‐energy optical bands and by
Chemical Stabilities of the Lowest Triplet State in Aryl Sulfones and Aryl Phosphine Oxides Relevant to OLED Applications
作者:Huifang Li、Minki Hong、Annabelle Scarpaci、Xuyang He、Chad Risko、John S. Sears、Stephen Barlow、Paul Winget、Seth R. Marder、Dongwook Kim、Jean-Luc Brédas
DOI:10.1021/acs.chemmater.8b04235
日期:2019.3.12
Aryl sulfones and phosphineoxides are widely used as molecular building blocks for host materials in the emissive layers of organic light-emitting diodes. In this context, the chemical stability of such molecules in the triplet state is of paramount concern to long-term device performance. Here, we explore the triplet excited-state (T1) chemical stabilities of aryl sulfonyl and aryl phosphoryl molecules
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.